Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

Thursday, May 9, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

PROTEOSTASIS THERAPEUTICS, INC.

 

CONDENSED STATEMENTS OF OPERATIONS

(In thousands, except share and per share amounts)

(Unaudited)

Three Months Ended March 31,

2019

2018

Revenue

$              5,000

$                 942

Operating expenses:

Research and development

16,148

8,400

General and administrative

3,943

3,823

Total operating expenses

20,091

12,223

Loss from operations

(15,091)

(11,281)

Interest income

357

165

Other income, net

316

90

Net loss

$          (14,418)

$          (11,026)

Net loss per share—basic and diluted

$              (0.28)

$              (0.32)

Weighted average common shares outstanding—basic and    diluted

50,976,907

34,474,004

PROTEOSTASIS THERAPEUTICS, INC.

 

CONDENSED BALANCE SHEET DATA

(In thousands)

(Unaudited)

March 31,

December 31,

2019

2018

Cash, cash equivalents and short-term investments

$           105,331

$           118,379

Total assets

123,493

136,142

Total liabilities

22,526

21,800

Total stockholders' equity

100,967

114,342



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store